Biomarker Research in Musculoskeleton Disease

描述（由申请人提供）：骨质疏松症是老年男性和女性的一个重要问题。最近的研究表明，骨骼生物标志物可能提供有关骨质疏松症生物学原因的重要信息，并且可能有助于单独预测骨折或与其他风险因素结合预测骨折。为了扩展他正在进行的NIH资助的生物标志物和骨骼脆弱性研究，弗朗西斯科加州大学医学、流行病学和生物统计学教授道格拉斯鲍尔博士，正在申请更新他的K24职业中期研究者奖，以患者为导向的研究，其科学目标是使用来自老年男性（MrOS）的良好特征纵向队列的数据开发新的临床有用的蛋白质组学生物标志物。利用正在进行的骨折评估和最近对基线时收集的血清中蛋白质组学测量的资助，本研究将在3000名MrOS参与者中探讨蛋白质组学谱与发生椎体骨折之间的前瞻性关系。通过与旧金山弗朗西斯科协调中心的长期合作，鲍尔博士将利用这些和其他来自多项大型研究的数据，继续指导对临床研究感兴趣的年轻研究人员，特别是住院医生。通过最初的K24奖项，鲍尔博士指导了现在正在追求更多研究培训和学术事业的居民和研究员。与UCSF临床和转化科学研究所一起，在最初的K24奖期间，他还开发并指导了一个新的综合住院医师研究计划。这个新计划的目标是通过为居民提供研究方法，试点资金和参与指导研究项目的机会的正式指导，促进临床研究事业。K24奖的延续对于保护Bauer博士的时间至关重要，并使他能够继续为与生物标志物和骨骼脆弱性相关的以患者为导向的研究做出重大贡献，并扩大他成功的指导计划。

DESCRIPTION (provided by applicant): Osteoporosis is a significant concern for both older men and women. Recent studies suggest skeletal biomarkers might provide important information about the biologic causes of osteoporosis and may be useful to predict fracture alone or when combined with other risk factors. To extend his ongoing NIH-funded work on biomarkers and skeletal fragility, Dr. Douglas Bauer, Professor of Medicine, Epidemiology & Biostatistics at the University of California, San Francisco, is requesting a renewal of his K24 Midcareer Investigator Award in Patient-Oriented Research with the scientific goals of developing new and clinically useful proteomic biomarkers using data from a well characterized longitudinal cohort of older men (MrOS). Taking advantage of ongoing assessments for fracture and recent funding for proteomic measurements in serum collected at baseline, this study will explore the prospective relationship between proteomic profile and incident vertebral fracture in 3000 MrOS participants. Using these and other data from multiple large studies available through his longstanding affiliation with the San Francisco Coordinating Center, Dr. Bauer will continue to mentor young investigators who are interested in clinical research, particularly residents. With the initial K24 award Dr. Bauer mentored residents and fellows who are now pursuing additional research training and academic careers. In conjunction with the UCSF Clinical and Translational Science Institute, during the initial K24 award he also developed and directed a new comprehensive Resident Research Program. The goal of this novel program is to promote clinical research careers by providing residents with formal instruction in research methods, pilot funding and opportunities to participate in mentored research projects. The continuation of this K24 award is critical to protect Dr. Bauer's time and allow him to continue to make significant contributions towards patient-oriented research related to biomarkers and skeletal fragility and to expand his successful mentoring program.